• European Patent Office issued intention to grant midkine antibody patent which covers one of the lead drugs in Cellmid’s midkine program
• This patent provides comprehensive protection over midkine antibodies in several disease settings including cancer, inflammatory diseases and autoimmune conditions
• Important milestone in clinical development program for midkine assets
• Significant value-add to the midkine patent portfolio for partnering
It adds value because Pfizer is running an array of Glioblastoma trials and they co-funded the Complutense pre-clinical study AND because the midkine antibody works in conjunction with other chemo.
My suggestion is the Pfizer will take this forward because of the results thus far.
Ann: Patent for Improved Midkine Antibody Allowed in Europe, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1197315 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 109888 | 2 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable